CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) ...

A new blood test called IsoPSA has been developed by researchers, that helps in detecting prostate cancer and reduces the rate of biopsies by almost 50 percent. IsoPSA, a new blood test detects ...

A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA ...

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer. Test results of patients ...

A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. Predicted probability of csPCa at biopsy.

A PSA or test prostate-specific antigen test after 50 years of age is usually advised to men to check on the status of their prostate gland. An elevated level of PSA in the blood is seen as an ...

The US Food and Drug Administration (FDA) has granted approval for Cleveland Diagnostics’ IsoPSA in vitro diagnostic (IVD) kit, designed as an aid for physicians in deciding on prostate biopsy for men ...

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an agreement designed to expand ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, ...